This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

An in depth discussion of the clinical landscape for Macular Edema, with a close look at Eylea and Regeneron's new data on its higher dosing versions

Ticker(s): REGN

Who's the expert?

Institution: UC San Diego

  • Associate professor of clinical ophthalmology who sees 600 patients a month with macular edema 
  • Medical degree at Albert Einstenin College of Medicince of Yeshiva University in New York; Residency at Washington University School of Medicine in St. Louis, Missouri
  • Clinical focus in vitreoretinal diseases and surgery
  • Research focus on developmental angiogenesis and the role of the Wnt signaling pathway 

Interview Goal
Discuss with a clinician the current landscape of medications for Macular edema, including retinal vein occlusion, wet/dry AMD, and diabetic retinopathy. Reviewing the impact of Eylea higher dose versions. 

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.